

**JUSTIFICATION FOR BRAND NAME PURCHASE IAW FAR 13.106-3(b)(3)(i)**  
(OVER MICRO-PURCHASE THRESHOLD(\$3K) BUT NOT EXCEEDING THE SAT (\$150K))

IAW [FAR13.104](#), COs must promote competition to the maximum extent practicable to obtain supplies and services from the source whose offer is the most advantageous to the Government, considering the administrative cost of the purchase. When competition is not practicable, IAW [FAR13.106-1\(b\)](#), COs solicit from a single source for purchases not exceeding the simplified acquisition threshold. COs may solicit from one source if the CO determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name or industrial mobilization). IAW [FAR13.106-3\(b\)\(3\)](#), COs are required to include additional statements ***explaining the absence of competition*** (see [13.106-1](#) for brand name purchases) if only one source is solicited and the acquisition does not exceed the simplified acquisition threshold (does not apply to an acquisition of utility services available from only one source) or supporting the award decision if other than price-related factors were considered in selecting the supplier. This template when completed can be used to document single source awards IAW [FAR13.106-3\(b\)\(3\)](#). Note: Statements such as "only known source" or "only source which can meet the required delivery date" are inadequate to support a sole source purchase.

**1. ACQUISITION PLAN ACTION ID:**

VA258-15-AP-4626

**1A. PROJECT/TASK  
No. N/A**

**1B. ESTIMATED AMOUNT:**

\$15,400.00

**2. BRIEF DESCRIPTION OF SUPPLIES REQUIRED AND THE INTENDED USE:** The VACSPCRPCC must purchase allopurinol, USP Active Pharmaceutical Ingredient (Allopurinol API) to manufacture 100 mg, 300 mg and 400 mg allopurinol tablets (Product) for VA research clinical trial CSP594 to study the use of allopurinol in veterans suffering from gout.

**3. UNIQUE CHARACTERISTICS THAT LIMIT AVAILABILITY TO A BRAND NAME ITEM, WITH THE REASON NO OTHER SUPPLIES CAN BE USED:** Allopurinol is subject medicine for the approved VA research clinical trial CSP594. There are no other medicines authorized to be used in the study. The reason for the study is to see if allopurinol will help veterans suffering from gout.

**4. REASON THAT SUGGESTED SOURCE IS THE ONLY SOURCE, WHICH CAN PROVIDE THE SUPPLIES OR SERVICES:**

Not Applicable: Market Research has shown that Multiple sources can provide the item designated for Brand Name Treatment.

**5. DESCRIPTION OF MARKET RESEARCH CONDUCTED AND RESULTS OR STATEMENT WHY IT WAS NOT CONDUCTED:** See Market Research In Contract file and results from FedBizOps Sources Sought.

**6. Contracting Officer's Certification:** *Purchase is approved in accordance with FAR13.106-1(b). I certify that the foregoing justification is accurate and complete to the best of my knowledge and belief. Price Reasonableness will be determined after quotes received. Market Research/ Sources Sought has shown that at least two vendors can provide the Brand Name Product.*

**Signature:** \_\_\_\_\_

**Date:** 12/30/2015

**Name:** Douglas Crowley

**Title:** Contracting Officer

**NCO:** 18